We are live on ! Find out more
EARNEST Partners

EARNEST Partners Portfolio holdings

AUM $27.7B
1-Year Est. Return 52.44%
This Fund
S&P 500
This Quarter Est. Return
+7.57%
1 Year Est. Return
+52.44%
3 Year Est. Return
+92.17%
5 Year Est. Return
+120.28%
10 Year Est. Return
+519.8%
AUM
$10B
AUM Growth
+$518M
Cap. Flow
-$105M
Cap. Flow %
-1.05%
Top 10 Hldgs %
18.87%
Holding
233
New
8
Increased
78
Reduced
133
Closed
4

Top Sells

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$99.4M
2
TSM icon
TSMC
TSM
+$29.1M
3
FPO
First Potomac Realty Trust
FPO
+$24.9M
4
ICLR icon
Icon
ICLR
+$16.9M
5
VWR
VWR Corporation
VWR
+$15.7M

Sector Composition

Rank Sector Weight
1 Financials 23.16%
2 Industrials 19.65%
3 Technology 15.19%
4 Healthcare 13.48%
5 Consumer Discretionary 9.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ANSS
101
DELISTED
Ansys
ANSS
$33.7M 0.34%
274,792
-5,725
-2% -$719K
ARW icon
102
Arrow Electronics
ARW
$10.4B
$32.6M 0.32%
+405,266
New +$32M
TSS
103
DELISTED
Total System Services, Inc.
TSS
$32.4M 0.32%
495,197
-21,681
-4% -$1.4M
HUM icon
104
Humana
HUM
$46.3B
$32.3M 0.32%
132,432
-7,333
-5% -$1.8M
SYF icon
105
Synchrony
SYF
$25.4B
$32.2M 0.32%
1,035,791
-43,063
-4% -$1.29M
BKI
106
DELISTED
Black Knight, Inc. Common Stock
BKI
$30.4M 0.3%
705,895
-24,575
-3% -$1.04M
CRL icon
107
Charles River Laboratories
CRL
$13.9B
$28.3M 0.28%
262,262
+20,683
+9% +$2.12M
WWD icon
108
Woodward
WWD
$20.2B
$26.2M 0.26%
337,968
-8,089
-2% -$570K
ARE icon
109
Alexandria Real Estate Equities
ARE
$8.87B
$26.2M 0.26%
220,058
+2,940
+1% +$353K
JBL icon
110
Jabil
JBL
$31.6B
$25.7M 0.26%
898,789
-34,859
-4% -$1.05M
NFX
111
DELISTED
Newfield Exploration
NFX
$25.6M 0.26%
862,684
+3,292
+0.4% +$88.4K
BIO icon
112
Bio-Rad Laboratories Class A
BIO
$10.4B
$25.5M 0.25%
114,771
-2,458
-2% -$553K
GPOR
113
DELISTED
Gulfport Energy Corp.
GPOR
$25.4M 0.25%
1,774,085
-2,847
-0.2% -$37K
XRAY icon
114
Dentsply Sirona
XRAY
$2.22B
$25.2M 0.25%
421,035
-1,418
-0.3% -$84.3K
MS icon
115
Morgan Stanley
MS
$337B
$25M 0.25%
518,573
-34,278
-6% -$1.59M
PKG icon
116
Packaging Corp of America
PKG
$21.4B
$24.5M 0.24%
214,010
-5,331
-2% -$596K
A icon
117
Agilent Technologies
A
$43.4B
$24.3M 0.24%
378,180
-9,415
-2% -$586K
CLR
118
DELISTED
CONTINENTAL RESOURCES INC.
CLR
$24.1M 0.24%
624,375
-28,331
-4% -$962K
UNH icon
119
UnitedHealth
UNH
$353B
$24.1M 0.24%
123,063
-6,024
-5% -$1.16M
R icon
120
Ryder
R
$9.43B
$23.5M 0.23%
277,591
+5,059
+2% +$383K
BXP icon
121
Boston Properties
BXP
$11.1B
$23M 0.23%
187,438
-7,994
-4% -$968K
WEC icon
122
WEC Energy
WEC
$34.6B
$22.9M 0.23%
364,098
-8,271
-2% -$528K
LH icon
123
Labcorp
LH
$27.2B
$22.7M 0.23%
174,846
-4,157
-2% -$554K
NSC icon
124
Norfolk Southern
NSC
$78.3B
$22.5M 0.22%
170,353
-10,433
-6% -$1.27M
ELV icon
125
Elevance Health
ELV
$85.5B
$22.4M 0.22%
118,067
-8,013
-6% -$1.53M

Similar funds

EARNEST Partners's Q3 2017 Portfolio in Review

As of Q3 2017, EARNEST Partners held 233 positions worth $10B, up 5.4% from $9.52B the previous quarter. Its ten largest holdings account for 19% of the portfolio.

EARNEST Partners's Q3 2017 filing shows 8 new, 78 increased, 133 reduced and 4 closed positions. Its largest new stake was Darling Ingredients: 3,984,504 shares worth $69.8M. The largest sale was Teva Pharmaceuticals, an estimated $99.4M.

By sector, the portfolio is most concentrated in Financials at 23% of assets, down from 23% a quarter earlier, followed by Industrials and Technology.

  • EARNEST Partners's largest Q3 2017 buy was Darling Ingredients: 3,984,504 shares worth $69.8M.
  • EARNEST Partners added most to Core Laboratories in Q3 2017, an estimated $11.2M increase.
  • EARNEST Partners's biggest Q3 2017 reduction was TSMC, cutting an estimated $29.1M.
  • EARNEST Partners fully exited Teva Pharmaceuticals in Q3 2017, selling an estimated $99.4M.
  • EARNEST Partners's ten largest holdings make up 19% of its $10B portfolio in Q3 2017.
  • EARNEST Partners opened 8 new positions and closed 4 in Q3 2017.
  • EARNEST Partners's portfolio value rose 5.4% quarter-over-quarter to $10B.

Based on EARNEST Partners's 13F filing for Q3 2017, filed 14 Nov 2017.